Palmitate-induced regulation of PPARγ via PGC1α: A mechanism for lipid accumulation in the liver in nonalcoholic fatty liver disease

International Journal of Medical Sciences

Volumn 13, Issue 3, 2016, Pages 169-178

  Maruyama, Hitoshi ^a   Kiyono, Soichiro ^a   Kondo, Takayuki ^a   Sekimoto, Tadashi ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Liver; Nonalcoholic fatty liver disease; Palmitate; Peroxisome proliferator activated receptor coactivator 1 ; Peroxisome proliferator activated receptor ; Triglyceride

Indexed keywords

CHOLESTEROL; OLEIC ACID; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SMALL INTERFERING RNA; TRIACYLGLYCEROL; PALMITIC ACID DERIVATIVE; PPARGC1A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; HUH7 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID ANALYSIS; LIPID METABOLISM; LIPID STORAGE; MALE; MOLECULAR DYNAMICS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; INBRED MOUSE STRAIN; LIVER; METABOLISM;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; LIPID METABOLISM; LIVER; MALE; MICE, INBRED STRAINS; NON-ALCOHOLIC FATTY LIVER DISEASE; OLEIC ACID; PALMITATES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; PPAR GAMMA; TRIGLYCERIDES; UP-REGULATION;

EID: 84975704385     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.13581     Document Type: Article

References (41)

1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Gastroenterological Association; American Association for the Study of Liver Diseases. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the american gastroenterological association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142:1592-1609.
3. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014; 2: 901-910.
4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55: 434-438.
5. Cortez-Pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol. 2006; 44: 197-208.
6. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003; 37: 1202-1219.
7. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43 (Suppl): S99-S112.
8. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alfa expression via a lysosomal pathway. Hepatology 2004; 40: 185-194.
9. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008; 103: 1036-1042.
10. Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Semin Liver Dis 2010; 30: 391-401.
11. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142: 711-725.
12. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013; 10: 627-636.
13. Ganz M, Szabo G. Immune and inflammatory pathways in NASH. Hepatol Int 2013; 7: S771-781.
14. Zhu Y, Alvares K, Huang Q, Rao MS, Reddy JK. Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem. 1993; 268: 26817-26820.
15. Braissant O, Foufellie F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPARα, -b and -g in the adult rat. Endocrinology 1996; 137: 354-366.
16. Jain S, Pulikuri S, Zhu Y, Qi C, Kanwar YS, Yeldandi AV, Rao MS, Reddy JK. Differential expression of the peroxisome proliferator-activated receptor g (PPAR g) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon and breast of the mouse. Am J Pathol. 1998; 153: 349-354.
17. Bortolini M, Wright MB, Bopst M, Balas B. Examining the safety of PPAR onists - current trends and future prospects. Expert Opin Drug Saf. 2013; 12: 65-79.
18. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med. 2013; 19: 557-566.
19. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferatorsactivated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000; 106: 523-531.
20. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, Tamura Y, Okazaki H, Yahagi N, Iizuka Y, Shionoiri F, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol. 2001; 21: 372-377.
21. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor- deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21: 365-371.
22. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 2006; 27: 728-735.
23. Austin S, St-Pierre J. PGC1α and mitochondrial metabolism-emerging concepts and lerevance in aging and neurodegenerative disorders. J Cell Sci. 2012; 125: 4963-4971.
24. Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K, Arumugam S, Watanabe K, Ichida T, Asakura H, Yoneyama H. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol 2013; 46: 141-152.
25. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226: 497-509.
26. Wei Y, Wang D, Gentile CL, Pagliassotti MJ. Reduced endoplasmic reticulum luminal calcium links saturated fatty acid-mediated endoplasmic reticulum stress and cell death in liver cells. Mol Cell Biochem. 2009; 331: 31-40.
27. Maruyama H, Takahashi M, Sekimoto T, Shimada T, Yokosuka O. Linoleate appears to protect against palmitate-induced inflammation in Huh7 cells. Lipids Health Dis. 2014; 1: 78.
28. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-1090.
29. Huss JM, Kopp RP, Kelly DP. Peroxisome Proliferator-activated Receptor Coactivator-1α(PGC-1α) Coactivates the Cardiac-enriched Nuclear Receptors Estrogen-related Receptor-α and γ. J Biol Chem. 2002; 277: 40265-46274.
30. St-Pierre J, Lin J, Krauss S, Tarr PT, Yang R, Newgard CB, Spiegelman BM. Bioenergetic analysis of peroxisome proliferator-activated receptor gamma coactivators 1alpha and 1beta (PGC-1alpha and PGC-1beta) in muscle cells. J Biol Chem. 2003; 278: 26597-26603.
31. Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M. PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res. 2005; 66: 562-573.
32. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, Handschin C, Zheng K, Lin J, Yang W Simon DK, Bachoo R, Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006; 127: 397-408.
33. Staiger H, Staiger K, Haas C, Weisser M, Machicao F, Haring HU. Fatty acid- induced differential regulation of the genes encoding peroxisome proliferator- activated receptor-γ coactivator-1α and -1β in human skeletal muscle cells that have been differentiated in vitro. Diabetologia 2005; 48: 2115-2118.
34. Coll T, Jove M, Rodriguez-Calvo R, Eyre E, Palomer X, Sanchez RM, Merlos M, Laguna JC, Vazquez-Carrera M. Palmitate-Mediated Downregulation of Peroxisome Proliferator-Activated Receptor-γ Coactivator 1α in Skeletal Muscle Cells Involves MEK1/2 and Nuclear Factor-κB Activation. Diabetes 2006; 55: 2779-2787.
35. Crunkhorn S, Dearie F, Mantzoros C, Gami H, da Silva WS, Espinoza D, Faucette R, Barry K, Bianco AC, Patti ME. Peroxisome Proliferator Activator Receptor γCoactivator-1 expression is reduced in obesity. Potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation. J Biol Chem. 2007; 282: 15439-15450.
36. Edvardsson U, Bergström M, Alexandersson M, Bamberg K, Ljung B, Dahllöf B. Rosiglitazone (BRL49653), a PPAR g-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res. 1999; 40: 1177-1184.
37. Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C, Feingold KR. Up-Regulation of Peroxisome Proliferator-Activated Receptors (PPAR-a) and PPAR-g Messenger Ribonucleic Acid Expression in the Liver in Murine Obesity: Troglitazone Induces Expression of PPAR-g-Responsive Adipose Tissue-Specific Genes in the Liver of Obese Diabetic Mice. Endocrinology 2000; 141: 4021-4031.
38. Pettinelli P, Videla LA. Up-Regulation of PPAR-γ mRNA Eexpression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab. 2011; 96: 1424-1430.
39. Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B Jr, Reitman ML, Gonzalez FJ. Liver-specific disruption of PPARgamma in leptin- deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest. 2003; 111: 737-747.
40. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML. Liver Peroxisome Proliferator- activated Receptor γContributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass. J Biol Chem. 2003; 278: 34268-34276.
41. Ricchi M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolotti M, Banni S, Lonardo A, Carulli N, Loria P. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol. 2009; 24: 830-840.